AR068509A1 - Antagosnistas del receptor de bradiquinina b1 - Google Patents

Antagosnistas del receptor de bradiquinina b1

Info

Publication number
AR068509A1
AR068509A1 ARP080104000A ARP080104000A AR068509A1 AR 068509 A1 AR068509 A1 AR 068509A1 AR P080104000 A ARP080104000 A AR P080104000A AR P080104000 A ARP080104000 A AR P080104000A AR 068509 A1 AR068509 A1 AR 068509A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
heteroaryl
heteroalkyl
heteroaralkyl
alkyl
Prior art date
Application number
ARP080104000A
Other languages
English (en)
Original Assignee
Jerini Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jerini Ag filed Critical Jerini Ag
Publication of AR068509A1 publication Critical patent/AR068509A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Tales compuestos son utiles para tratar enfermedades o aliviar síntomas adversos asociados con inflamacion y dolor. La invencion abarca compuestos novedosos el uso de los mismos para preparar medicamentos, composiciones farmacéuticas y métodos para la profilaxis y el tratamiento de enfermedades que implican inflamacion y dolor. Reivindicacion 1: Un compuesto de la formula (1): o una sal aceptable para uso farmacologico, solvato o hidrato del mismo, donde A es: i) un cicloalquilo de 5 o 6 miembros sustituido en forma opcional; ii) un heterocicloalquilo de 5 o 6 miembros sustituido en forma opcional; iii) un arilo de 5 o 6 miembros sustituido en forma opcional; o iv) un heteroarilo de 5 o 6 miembros sustituido en forma opcional; T es un átomo de hidrogeno, o se une a B para formar i) un heterocicloalquilo sustituido en forma opcional; o ii) un heteroarilo sustituido en forma opcional; B es un alquilo sustituido en forma opcional, un alquenilo sustituido en forma opcional, un alquinilo sustituido en forma opcional, un heteroalquilo sustituido en forma opcional, un cicloalquilo sustituido en forma opcional, un heterocicloalquilo sustituido en forma opcional, un alquicicloalquilo sustituido en forma opcional, un heteroalquilcicloalquilo sustituido en forma opcional, un arilo sustituido en forma opcional, un heteroarilo sustituido en forma opcional, un aralquilo sustituido en forma opcional, un heteroaralquilo sustituido en forma opcional, o (2) donde W es N, alquilo, heteroalquilo, alquenilo, cicloalquilo, alquilcicloalquilo, heteroalquilcicloalquilo, arilo, heteroarilo, aralquilo o heteroaralquilo; R4, si está presente, es un átomo de hidrogeno, un alquilo sustituido en forma opcional, un heteroalquilo sustituido en forma opcional, un alquilcicloalquilo sustituido en forma opcional, heteroalquilcicloalquilo sustituido en forma opcional, un arilo sustituido en forma opcional, un aralquilo sustituido en forma opcional, un heteroaralquilo sustituido en forma opcional o se une a para formar, junto con W, i) un cicloalquilo sustituido en forma opcional; ji) un heterocicloalquilo sustituido en forma opcional; iii) un arilo sustituido en forma opcional; o iv) un heteroarilo sustituido en forma opcional; R5, si está presente, es un átomo de hidrogeno, un alquilo sustituido en forma opcional, un heteroalquilo sustituido en forma opcional, heteroalquilcicloalquilo sustituido en forma opcional, un arilo sustituido en forma opcional, un aralquilo sustituido en forma opcional, un heteroaralquilo sustituido en forma opcional o se une a para formar, junto con W, i) un cicloalquilo sustituido en forma opcional; ii) un heterocicloalquilo sustituido en forma opcional; iii) un arilo sustituido en forma opcional; o iv) un heteroarilo sustituido en forma opcional; E, si está presente, es un heteroalquilo o un heteroaralquilo; G, si está presente, es un alquilo, un heteroalquilo, un cicloalquilo, un heterocicloalquilo, un alquilcicloalquilo, un heterocicloalquilalquilo, un heteroarilo o un heteroaralquilo K es (3) donde R1 y R2 se seleccionan cada uno en forma independiente de alquilo C2-6, alquenilo C2-6, alquinilo C2-6, heteroalquilo C2-6, o forman, junto con N, un heterocicloalquilo sustituido en forma opcional, un heteroarilo sustituido en forma opcional o un heteroaralquilo sustituído en forma opcional; y es un átomo de hidrogeno, alquilo C1 o C2, ciano o un átomo de halogeno.
ARP080104000A 2007-09-19 2008-09-15 Antagosnistas del receptor de bradiquinina b1 AR068509A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07018396 2007-09-19

Publications (1)

Publication Number Publication Date
AR068509A1 true AR068509A1 (es) 2009-11-18

Family

ID=40268352

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104000A AR068509A1 (es) 2007-09-19 2008-09-15 Antagosnistas del receptor de bradiquinina b1

Country Status (7)

Country Link
EP (1) EP2195288A2 (es)
JP (1) JP2010539204A (es)
AR (1) AR068509A1 (es)
AU (1) AU2008300822A1 (es)
CA (1) CA2700051A1 (es)
TW (1) TW200930710A (es)
WO (1) WO2009036996A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009132453A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
EP2344176A1 (en) * 2008-09-18 2011-07-20 Jerini AG Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
MY177250A (en) 2010-06-30 2020-09-10 Fujifilm Corp Novel nicotinamide derivative or salt thereof
US8937073B2 (en) * 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
NO2799431T3 (es) 2011-12-28 2018-06-23
TW201609652A (zh) * 2013-11-12 2016-03-16 陶氏農業科學公司 用於氟化化合物之過程（三）
EP3558972A1 (en) 2016-12-23 2019-10-30 Bayer Pharma Aktiengesellschaft Tetrazole containing compounds
US12023319B2 (en) 2016-12-23 2024-07-02 Bayer Pharma Aktiengesellschaft Carboxylic acid aromatic amides
JOP20190156B1 (ar) 2016-12-23 2023-09-17 Bayer Pharma AG أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
AR118982A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
WO2022070023A1 (en) * 2020-09-29 2022-04-07 Oat & Iil India Laboratories Private Limited Novel piperazine compound or the salt thereof for use as pesticides
WO2024059495A1 (en) * 2022-09-12 2024-03-21 The Regents Of The University Of California Methods of preparing ergoline analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH441366A (de) * 1961-06-09 1967-08-15 Hoffmann La Roche Verfahren zur Herstellung von substituierten Hydrazinverbindungen
JPH0641455B2 (ja) * 1984-12-10 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IE914218A1 (en) * 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
FR2790472B1 (fr) * 1999-03-04 2001-04-06 Synthelabo Derives de cyclobutene-3, 4-dione, leur preparation et leur application en therapeutique
FR2792635B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique
PL360294A1 (en) * 2000-07-05 2004-09-06 Yamanouchi Pharmaceutical Co.Ltd. Propane-1,3-dione derivatives
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
SE0104326D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic heterocycles
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7414047B2 (en) * 2002-10-23 2008-08-19 Janssen Pharmaceutica N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
ES2298621T3 (es) * 2002-11-02 2008-05-16 Sanofi-Aventis Deutschland Gmbh Nuevas diamidas del acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de colagenasas.
WO2005014576A1 (ja) * 2003-08-12 2005-02-17 Takeda Pharmaceutical Company Limited イソキノリノン誘導体、その製造法および用途
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050261327A1 (en) * 2004-05-20 2005-11-24 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation
EP1884513A4 (en) * 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
JP2007191461A (ja) * 2005-05-23 2007-08-02 Japan Tobacco Inc ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2008123582A1 (ja) * 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物

Also Published As

Publication number Publication date
JP2010539204A (ja) 2010-12-16
EP2195288A2 (en) 2010-06-16
CA2700051A1 (en) 2009-03-26
AU2008300822A1 (en) 2009-03-26
WO2009036996A2 (en) 2009-03-26
WO2009036996A3 (en) 2009-06-18
TW200930710A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
AR068509A1 (es) Antagosnistas del receptor de bradiquinina b1
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
AR081203A1 (es) Pirrolopirazinas como inhibidores de quinasas
BR112015032637A2 (pt) derivados de pirrolopiridina ou pirazolopiridina
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR077440A1 (es) Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
AR089019A1 (es) Derivados modificados de 4-fenil-piridina
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
CL2008001669A1 (es) Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.
CO6251201A2 (es) Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos
CO6160260A2 (es) Compuestos derivados de alquinil fenilo para tratar enfermedades y desordenes oftalmicos
EA201291246A1 (ru) Конденсированные бициклические ингибиторы киназы
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
PE20091524A1 (es) Derivados de 2-aminopirimidina
AR061656A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
DOP2021000045A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inihibidores de ccr6
BR112012020557A8 (pt) formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
AR065333A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
MA50093B1 (fr) Composé pentacyclique
PE20212113A1 (es) Inhibidores de moleculas pequenas de la familia de quinasas jak
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора

Legal Events

Date Code Title Description
FA Abandonment or withdrawal